Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study used a retrospective single cohort pre-post design on Optum® Clinformatics® Data Mart (CDM) data from 20 August 2019 to 31 December 2023 (study period). Patients with a diagnosis of multiple sclerosis (MS) treated with ofatumumab (OMB) between 20 August 2020 (U.S. Food and Drug Administration [FDA] approval date) and 01 July 2023 (patient identification window) were included in the study population. The date of the first OMB claim within the patient identification window was defined as the index date. Outcomes, including annualized relapse rate (ARR) and MS-related healthcare resource utilization (HCRU), were measured across two distinct periods. The pre-index period was defined as the fixed 12-month period prior to the index date, during which demographic and clinical characteristics were also assessed. The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another disease modifying therapy [DMT]), discontinuation of enrollment, or end of study period on 31 December 2023.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ofatumumab MS Cohort | Adult patients diagnosed with MS who were treated with ofatumumab. | ||
| Anti-CD20-naïve Sub-cohort | Adult patients diagnosed with MS who were treated with ofatumumab and had not received anti-CD20 treatment. | ||
| Anti-CD20-experienced Sub-cohort | Adult patients diagnosed with MS who were treated with ofatumumab and had previously received anti-CD20 treatment. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Annualized Relapse Rate (ARR) in the Pre-Index Period | The pre-index period was defined as the fixed 12-month period prior to the index date. The index date was the date of the first OMB claim. The ARR was defined as the number of relapse events per person-year. | 12 months |
| ARR in the Post-index Period | The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another disease modifying therapy [DMT]), discontinuation of enrollment, or end of study period. The index date was the date of the first OMB claim. The ARR was defined as the number of relapse events per person-year. | An average of approximately 16 months |
| Incidence Rate Ratio | Incidence rate ratio was measured to evaluate the change in MS-related ARR in the pre- versus the post-index period. The index date was the date of the first OMB claim. The pre-index period was defined as the fixed 12-month period prior to the index date. The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another DMT), discontinuation of enrollment, or end of study period. | An average of approximately 16 months |
| Measure | Description | Time Frame |
|---|---|---|
| Age | Baseline | |
| Number of Patients per Demographic Category | Demographic categories included:
|
Not provided
Inclusion criteria:
Exclusion criteria:
None.
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis | East Hanover | New Jersey | 07936 | United States |
Not provided
| Label | URL |
|---|---|
| Results for COMB157AUS21 from the Novartis Clinical Trials Website | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline |
| Mean Deyo-Charlson Comorbidity Index | Deyo-Charlson Comorbidity Index predicts the ten-year mortality for a patient who may have a range of comorbid conditions. Comorbidity was assessed using the Charlson Comorbidity Index (CCI), categorized as low (0-1) and high (≥2). | Baseline |
| Mean Number of Psychiatric Diagnostic Group (PDG) Mental Health Disorders | PDG captures a list of mental health disorders a patient may have at study baseline. The following are the list of PDGs:
| Baseline |
| Number of Patients Categorized by Top Five Selected Comorbidities | Top five selected comorbidities included osteoarthritis, dyslipidemia, depression, hypertension, and sleep disorders. | Baseline |
| Number of Patients Categorized by Top Five MS-related Symptoms and Secondary Conditions | Top five MS-related symptoms and secondary conditions included anxiety, fatigue or malaise, sensory problems, eye symptoms, and urinary tract infection. | Baseline |
| Number of Patients Categorized by MS Disability Level | MS disability level was based on observance of Expanded Disability Status Scale (EDSS)-related symptoms and durable medical equipment (DME) use observed in claims data weighted by severity score. Disability levels and definitions were as follows: Severe = Defined as having ≥1 EDSS-related symptom with severity score = 3 in any functional system; Moderate: Defined as having ≥1 EDSS-related symptom with severity score = 2 in any functional system, or having ≥2 functional systems with severity score = 1; Mild: Defined as having only one EDSS-related symptom with severity score = 1 or having no EDSS-related symptoms observed during the measurement period. | Baseline |
| Number of Patients Categorized by DMT Used in the Pre-index Period | DMT categories included:
| Baseline |
| Pre-index Healthcare Resource Utilization (HCRU): Number of MS-related Hospitalizations per Person-year (PPY) | The pre-index period was defined as the fixed 12-month period prior to the index date. The index date was the date of the first OMB claim. | 12 months |
| Pre-index HCRU: Number of Days of MS-related Hospitalization PPY | The pre-index period was defined as the fixed 12-month period prior to the index date. The index date was the date of the first OMB claim. | 12 months |
| Pre-index HCRU: Number of MS-related Healthcare Visits PPY | The pre-index period was defined as the fixed 12-month period prior to the index date. The index date was the date of the first OMB claim. MS-related healthcare visits included emergency department visits and outpatient visits. | 12 months |
| Post-index HCRU: Number of MS-related Hospitalizations PPY | The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another DMT), discontinuation of enrollment, or end of study period. The index date was the date of the first OMB claim. | An average of approximately 16 months |
| Post-index HCRU: Number of Days of MS-related Hospitalization PPY | The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another DMT), discontinuation of enrollment, or end of study period. The index date was the date of the first OMB claim. | An average of approximately 16 months |
| Post-index HCRU: Number of MS-related Healthcare Visits PPY | The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another DMT), discontinuation of enrollment, or end of study period. The index date was the date of the first OMB claim. MS-related healthcare visits included emergency department visits and outpatient visits. | An average of approximately 16 months |
| Incidence Rate Ratio of MS-related Hospitalizations | Incidence rate ratio was measured to evaluate the change in MS-related hospitalizations in the pre- versus the post-index period. The index date was the date of the first OMB claim. The pre-index period was defined as the fixed 12-month period prior to the index date. The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another DMT), discontinuation of enrollment, or end of study period. | An average of approximately 16 months |
| Incidence Rate Ratio of Days of MS-related Hospitalizations | Incidence rate ratio was measured to evaluate the change in days of MS-related hospitalizations in the pre- versus the post-index period. The index date was the date of the first OMB claim. The pre-index period was defined as the fixed 12-month period prior to the index date. The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another DMT), discontinuation of enrollment, or end of study period. | An average of approximately 16 months |
| Incidence Rate Ratio of MS-related Emergency Department Visits | Incidence rate ratio was measured to evaluate the change in MS-related emergency department visits in the pre- versus the post-index period. The index date was the date of the first OMB claim. The pre-index period was defined as the fixed 12-month period prior to the index date. The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another DMT), discontinuation of enrollment, or end of study period. | An average of approximately 16 months |
| Incidence Rate Ratio of MS-related Outpatient Visits | Incidence rate ratio was measured to evaluate the change in MS-related outpatient visits in the pre- versus the post-index period. The index date was the date of the first OMB claim. The pre-index period was defined as the fixed 12-month period prior to the index date. The post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent OMB use (defined as last day of OMB supply before a gap of ≥60 days or switch to another DMT), discontinuation of enrollment, or end of study period. | An average of approximately 16 months |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |